Evidence map›Paper›PMID 41074980›Full record

ArticleJournal of gastroenterology2025

Hepatitis B core-related antigen kinetics predict spontaneous HBeAg seroclearance in chronic hepatitis B patients.

Hung-Yao Lin, Kuan-Hui Hsin, Chun-Jen Liu, Tung-Hung Su, Wan-Ting Yang, Shang-Chin Huang, Shih-Jer Hsu, Hung-Chih Yang, Chen-Hua Liu, Pei-Jer Chen and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hung-Yao Lin *Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Kuan-Hui Hsin *Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Chun-Jen LiuDivision of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Tung-Hung SuDivision of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Wan-Ting YangHepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan.
Shang-Chin HuangDivision of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Shih-Jer HsuDivision of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Hung-Chih YangDivision of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Chen-Hua LiuDivision of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Pei-Jer ChenDivision of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Tai-Chung Tseng *Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. tctsenghbv@gmail.com.
Jia-Horng Kao *Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. kaojh@ntu.edu.tw.ORCID 0000-0002-2442-7952

Funding

National Science and Technology Council MOST 109-2314-B-002-086National Science and Technology Council MOST 110-2314-B-002 -040National Taiwan University Hospital 109-N4644National Taiwan University Hospital 109-P05National Taiwan University Hospital 110-EDN08National Taiwan University Hospital 110-N4850National Taiwan University Hospital 110-P06National Taiwan University Hospital 111N0067
6 · The paper itself

Abstract

BACKGROUND AND

aimsHepatitis B e antigen (HBeAg) seroclearance is crucial in the natural history of chronic hepatitis B (CHB). Little is known about the role of hepatitis B core-related antigen (HBcrAg) levels in predicting spontaneous HBeAg seroclearance.

methodsThis retrospective cohort study included 484 treatment-naïve HBeAg-positive CHB patients with an extended follow-up period at National Taiwan University Hospital. The primary endpoint was spontaneous seroclearance of HBeAg. The association between baseline HBcrAg levels and their kinetic patterns with spontaneous HBeAg seroclearance was assessed.

resultsOf 484 patients with a mean follow-up period of 7.80 years, 331 (68.4%) achieved spontaneous HBeAg seroclearance, corresponding to an annual rate of 8.76%. Lower baseline HBcrAg levels correlated with an increased likelihood of HBeAg seroclearance (log-rank P < .001). When HBcrAg kinetics were assessed based on baseline and year 3 levels, patients with HBcrAg levels persistently < 10

conclusionsHBcrAg < 10

Indexed as

Hepatitis B, ChronicHepatitis B Core AntigensHepatitis B e AntigensAdultCohort StudiesFemaleFollow-Up StudiesHumansKineticsMaleMiddle AgedRemission, SpontaneousRetrospective StudiesTaiwanHepatitis B Core AntigensHepatitis B e AntigensChronic hepatitis BERADICATE-BHBcrAgHBeAg lossHBV DNAImmune tolerant phase

Identifiers

PMID41074980

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.